Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06810960 · ClinicalTrials.gov registry record
A Postmarketing Study of Lecanemab in South Korean Participants With Alzheimer's Disease
A clinical trial of Alzheimers Disease, sponsored by Eisai Korea.
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 1
- Study location
NCT06810960 is a study of Alzheimers Disease that is actively recruiting participants, run by Eisai Korea. The registered enrollment target is 3,000 participants, below the 4,040-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (26% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06810960, a study of Alzheimers Disease, is actively recruiting participants, sponsored by Eisai Korea.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to evaluate safety of lecanemab in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 centimeter (cm) in participants treated with lecanemab.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (1)
New Jersey
- Eisai Trial Site #1 - Nutley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2025-02-24 |
| Est. Completion | 2029-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06810960
The ClinicalTrials.gov registry entry for NCT06810960 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,040-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (26% lower). The listed sponsor is Eisai Korea, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT06810960 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT06810960 about?
NCT06810960 is a clinical study titled "A Postmarketing Study of Lecanemab in South Korean Participants With Alzheimer's Disease". The primary purpose of this study is to evaluate safety of lecanemab in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (IC...
What is the current status of trial NCT06810960?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2025-02-24. Estimated completion is 2029-12-31.
What conditions does trial NCT06810960 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT06810960?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT06810960?
This trial is sponsored by Eisai Korea, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06810960 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
University of Central Florida Music Study
RECRUITING · NA
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.